Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening
heart failure events and cardiovascular death comparing to placebo in patients with reduced
ejection fraction further to standard of care. However, hypotensive patients who generally
have higher risks comparing to normotensive patients, were under represented in the DAPA-HF.
The investigators aimed to evaluate clinical effects of dapagliflozin on hypotensive heart
failure patients receiving chronic sacubitril/valsartan treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Cheng-Hsin General Hospital
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol Adrenergic beta-Antagonists Carvedilol Dapagliflozin LCZ 696 Mineralocorticoid Receptor Antagonists Mineralocorticoids Sacubitril and valsartan sodium hydrate drug combination Valsartan